Tech Company Financing Transactions

Tolero Pharmaceuticals Funding Round

Fred Alger Management participated in a $8 million Series B funding round for Tolero Pharmaceuticals. The round closed on 11/5/2014.

Transaction Overview

Announced On
11/5/2014
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Series B
Investors

Fred Alger Management (Lead Investor)

Proceeds Purpose
Proceeds will support the further development and commercialization of Tolero's lead program, alvocidib, which is being developed for the treatment of acute myeloid leukemia (AML) and the ongoing advancement of its preclinical pipeline. Tolero plans to initiate Phase 3 clinical trials of alvocidib in patients with AML and clinical trials of two of its preclinical programs in 2015.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3900 N Traverse Mountain Blvd. 100
Lehi, UT 84043
USA
Email Address
Not Recorded
Overview
Tolero Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to alleviating human suffering through the discovery and development of novel therapeutics to treat cancer and other serious human diseases. Our pipeline targets important biological drivers of blood disorders to treat leukemias and anemia.
Profile
Tolero Pharmaceuticals LinkedIn Company Profile
Social Media
Tolero Pharmaceuticals Company Twitter Account
Company News
Tolero Pharmaceuticals News
Facebook
Tolero Pharmaceuticals on Facebook
YouTube
Tolero Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
David Bearss
  David Bearss LinkedIn Profile  David Bearss Twitter Account  David Bearss News  David Bearss on Facebook
Chief Financial Officer
David Sampson
  David Sampson LinkedIn Profile  David Sampson Twitter Account  David Sampson News  David Sampson on Facebook
Chief Operating Officer
Michael McCullar
  Michael McCullar LinkedIn Profile  Michael McCullar Twitter Account  Michael McCullar News  Michael McCullar on Facebook
Vice President
Kotaro Hirota
  Kotaro Hirota LinkedIn Profile  Kotaro Hirota Twitter Account  Kotaro Hirota News  Kotaro Hirota on Facebook
VP - Bus. Development
Katsumi Tanaka
  Katsumi Tanaka LinkedIn Profile  Katsumi Tanaka Twitter Account  Katsumi Tanaka News  Katsumi Tanaka on Facebook
VP - Bus. Development
Steven Warner
  Steven Warner LinkedIn Profile  Steven Warner Twitter Account  Steven Warner News  Steven Warner on Facebook
VP - R & D
Stephen Anthony
  Stephen Anthony LinkedIn Profile  Stephen Anthony Twitter Account  Stephen Anthony News  Stephen Anthony on Facebook
VP - Regulatory Affairs
Michael Bernstein
  Michael Bernstein LinkedIn Profile  Michael Bernstein Twitter Account  Michael Bernstein News  Michael Bernstein on Facebook


 

 

Browse more venture capital transactions:

Prev: 11/5/2014: Eaze venture capital transaction
Next: 11/5/2014: Pendo venture capital transaction

 

Share this article

 


Where The Data Comes From

Our team works diligently to report on tech company VC transactions. All VC database entries reported here are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary